➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKinsey
Colorcon
Express Scripts
Harvard Business School

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,402,916

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,402,916
Title:Re-directed immunotherapy
Abstract: The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
Inventor(s): Cobbold; Mark (Birmingham, GB), Millar; David (Birmingham, GB)
Assignee: THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB)
Application Number:14/005,452
Patent Claims:1. A method of retargeting T cells to cancer cells, the method comprising administering an agent for treating cancer to a human subject in need thereof, wherein the agent comprises: i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is an antibody or antigen binding fragment thereof that binds a tumor antigen; and ii) a viral T cell epitope that elicits an existing immune response in the subject and binds to a HLA molecule on the surface of the cancer cell of the human subject and has a HLA matched to the subject, and iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the cancer cell.

2. The method according to claim 1, further comprising determining any one of (i) HLA alleles of the subject, (ii) cytotoxic T cell response of the subject to a T cell epitope (iii) expression profile of the cancer cell in the subject.

3. The method according to claim 1, further comprising administering a therapeutic agent suitable for treating cancer.

4. The method of claim 1, wherein the antibody is Rituximab or Cetuximab.

5. The method of claim 1, wherein the T cell epitope is a peptide from Varicella Zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus, adenovirus, rhinovirus, or influenza virus.

6. The method of claim 1, wherein the T cell epitope is a cytomegalovirus peptide.

7. The method of claim 1, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21), TPRVTGGGAM (SEQ ID NO: 31), DYSNTHSTRYV (SEQ ID NO: 55), YVLEETSVM (SEQ ID NO: 3), or VLEETSVML (SEQ ID NO: 4).

8. The method of claim 1, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21).

9. The method of claim 1, wherein the antibody or antigen binding fragment thereof is specific for any of Her2/Neu; CD22; EpCAM (CD326); EGFR; PMSA; CD30; CD20; CD33; membrane IgE; IgE Receptor (CD23), CD80; CD86; CD2; CA125; Carbonic Anhydrase IX; CD70; CD74; CD56; CD40; CD19; c-met/HGFR; TRAIL-R1; DR5; PD-1; PD1L; IGF-1R; VEGF-R2; Prostate stem cell antigen (PSCA); MUC1; CanAg; Mesothelin; P-cadherin; Myostatin (GDF8); Cripto (TDGF1); ACVRL1/ALK1; MUC5AC; CEACAM; SLC44A4; CD2/CS1; CD137; CXCR4; Neuropilin 1; Glypican; HER3/EGFR; PDGFRa, EphA2, CD22, E-cadherin, FGFR3, and CD138.

10. The method of claim 1, wherein the antibody or antigen binding fragment thereof binds to CD20 or EGFR and the T cell epitope is a cytomegalovirus peptide.

11. The method of claim 10, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21).

12. The method of claim 1, wherein the tumor associated protease is a cysteine protease, an aspartyl protease, a serine protease, or a metalloprotease.

13. The method of claim 1, wherein the tumor associated protease is Cathepsin B, Cathepsin L, Cathepsin S, Cathepsin D, Cathepsin E, Cathepsin A, Cathepsin G, Thrombin, Plasmin, Urokinase, Tissue Plasminogen Activator, Metalloproteinase 1 (MMP1), MMP2, MMP3, MMP4, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP20, MMP21, MMP23, MMP24, MMP25, MMP26, MMP28, ADAM, ADAMTS, CD10 (CALLA), or prostate specific antigen.

14. The method of claim 1, wherein the tumor associated protease is a metalloprotease or a cathepsin.

15. The method of claim 1, wherein the tumor associated protease is MMP2, ADAM28, or Cathepsin B.

16. The method of claim 11, wherein the tumor associated protease is ADAM28.

17. The method of claim 1, wherein the T cell epitope is an MHC Class I restricted antigen, an MHC Class II restricted antigen, or an antigen that is capable of binding to a group I CD1 molecule.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1104514.3Mar 17, 2011
United Kingdom1203434.4Feb 28, 2012
PCT Information
PCT FiledMarch 15, 2012PCT Application Number:PCT/GB2012/050577
PCT Publication Date:September 20, 2012PCT Publication Number:WO2012/123755

Details for Patent 9,402,916

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB) 2031-03-17 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB) 2031-03-17 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB) 2031-03-17 DISCN search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB) 2031-03-17 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB) 2031-03-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
McKinsey
Moodys
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.